Therefore, selective inhibition of JAK3 represents a promising yet underexplored approach in cancer therapeutics, with potential applications extending beyond hematologic malignancies to solid tumors exhibiting aberrant JAK/STAT pathway activation [13–15]. Here, JAK3 is linked to cancer.